Results from a phase 1-2 clinical study (NCT05296122) 1 showed that safety and feasibility measures among patients with primary and recurrent glioblastoma and grade 4 astrocytoma could be met using ...

An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation ...

The Paloma-3 study provided important insights into patient-reported outcomes with the subcutaneous formulation of amivantamab. Historically, cancer treatment focused primarily on ...

An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent ...

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, ...

The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...

Received folinic acid/fluorouracil/oxaliplatin/bevacizumab in first line with initial partial response; progression after 11 ...

Peers & Perspectives in Oncology | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine ...

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming ...

Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...

The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...